BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 7
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report
©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3357-3363
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3357
Figure 3
Full Size Figure Download Figure
Figure 3 Schema of class II BRAF mutation and action of encorafenib, binimetinib, and cetuximab. This schema was created with BioRender.com.
  • Citation: Sasaki M, Shimura T, Nishie H, Kuroyanagi K, Kanno T, Fukusada S, Sugimura N, Mizuno Y, Nukui T, Uno K, Kojima Y, Nishigaki R, Tanaka M, Ozeki K, Kubota E, Kataoka H. BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. World J Gastrointest Oncol 2024; 16(7): 3357-3363
  • URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3357.htm
  • DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3357
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.